These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease. Barry MA; Wang Q; Jones KM; Heffernan MJ; Buhaya MH; Beaumier CM; Keegan BP; Zhan B; Dumonteil E; Bottazzi ME; Hotez PJ Hum Vaccin Immunother; 2016 Apr; 12(4):976-87. PubMed ID: 26890466 [TBL] [Abstract][Full Text] [Related]
9. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice. Bhatia V; Garg NJ Clin Vaccine Immunol; 2008 Aug; 15(8):1158-64. PubMed ID: 18550728 [TBL] [Abstract][Full Text] [Related]
10. Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. Frank FM; Petray PB; Cazorla SI; Muñoz MC; Corral RS; Malchiodi EL Vaccine; 2003 Dec; 22(1):77-86. PubMed ID: 14604574 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant effect of the Propionibacterium acnes and its purified soluble polysaccharide on the immunization with plasmidial DNA containing a Trypanosoma cruzi gene. Mussalem JS; Vasconcelos JR; Squaiella CC; Ananias RZ; Braga EG; Rodrigues MM; Longo-Maugéri IM Microbiol Immunol; 2006; 50(4):253-63. PubMed ID: 16625047 [TBL] [Abstract][Full Text] [Related]
12. A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection. Barry MA; Versteeg L; Wang Q; Pollet J; Zhan B; Gusovsky F; Bottazzi ME; Hotez PJ; Jones KM PLoS Negl Trop Dis; 2019 May; 13(5):e0007413. PubMed ID: 31145733 [TBL] [Abstract][Full Text] [Related]
13. Trypanosoma cruzi: protective immunity in mice immunized with paraflagellar rod proteins is associated with a T-helper type 1 response. Miller MJ; Wrightsman RA; Manning JE Exp Parasitol; 1996 Nov; 84(2):156-67. PubMed ID: 8932765 [TBL] [Abstract][Full Text] [Related]
14. Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Seid CA; Jones KM; Pollet J; Keegan B; Hudspeth E; Hammond M; Wei J; McAtee CP; Versteeg L; Gutierrez A; Liu Z; Zhan B; Respress JL; Strych U; Bottazzi ME; Hotez PJ Hum Vaccin Immunother; 2017 Mar; 13(3):621-633. PubMed ID: 27737611 [TBL] [Abstract][Full Text] [Related]
15. Tc52 amino-terminal-domain DNA carried by attenuated Salmonella enterica serovar Typhimurium induces protection against a Trypanosoma cruzi lethal challenge. Matos MN; Cazorla SI; Bivona AE; Morales C; Guzmán CA; Malchiodi EL Infect Immun; 2014 Oct; 82(10):4265-75. PubMed ID: 25069980 [TBL] [Abstract][Full Text] [Related]
16. Experimental Chagas disease in Balb/c mice previously vaccinated with T. rangeli. II. The innate immune response shows immunological memory: reality or fiction? Basso B; Marini V Immunobiology; 2015 Mar; 220(3):428-36. PubMed ID: 25454810 [TBL] [Abstract][Full Text] [Related]
17. Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection. Cerny N; Sánchez Alberti A; Bivona AE; De Marzi MC; Frank FM; Cazorla SI; Malchiodi EL Hum Vaccin Immunother; 2016; 12(2):438-50. PubMed ID: 26312947 [TBL] [Abstract][Full Text] [Related]
18. A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease. Serna C; Lara JA; Rodrigues SP; Marques AF; Almeida IC; Maldonado RA Vaccine; 2014 Jun; 32(28):3525-32. PubMed ID: 24793944 [TBL] [Abstract][Full Text] [Related]